Theriva Biologics, Inc. (TOVX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Theriva Biologics, Inc. is a clinical-stage biopharmaceutical company that transitioned its strategic focus to oncology following the 2022 acquisition of VCN Biosciences. The Company's lead product candidate is VCN-01, an oncolytic adenovirus for the treatment of solid tumors, including pancreatic ductal adenocarcinoma (PDAC) and retinoblastoma. The Company also maintains legacy gastrointestinal (GI) assets, SYN-004 and SYN-020, which it is exploring for out-licensing or partnership opportunities.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(13,058) | $(8,316) | $(17,382) | $(13,481) |
| Net Loss Per Share (Basic/Diluted) | $(1.93) | $(10.72) | $(3.64) | $(18.45) |
| Cash and Cash Equivalents (End of Period) | $12,120 | $16,593 | $12,120 | $16,593 |
| Working Capital | $2,349 | $8,696 | $2,349 | $8,696 |
| Accumulated Deficit | $(352,353) | $(322,799) | $(352,353) | $(322,799) |
| Total Debt (Current + Non-Current) | $1,695 | $153 | $1,695 | $153 |
Note: Revenue is $0 as the Company has no commercial products. Working Capital is calculated as Total Current Assets ($14,743) minus Total Current Liabilities ($12,394).
Material Changes vs. Prior Period
- General and Administrative (G&A) Expenses: Increased significantly to $11.2 million in Q2 2025 from $1.5 million in Q2 2024. This 662% increase was primarily driven by a $9.2 million non-cash fair value adjustment to contingent consideration liabilities. This adjustment occurred because the Company met the primary survival and safety endpoints in the VIRAGE Phase 2b clinical trial for VCN-01, triggering a milestone payment obligation.
- Research and Development (R&D) Expenses: Decreased to $2.0 million in Q2 2025 from $3.0 million in Q2 2024. The reduction is attributed to lower clinical trial expenses for the VIRAGE trial and reduced manufacturing costs, partially offset by higher patent expenses for SYN-020.
- Goodwill Impairment: No impairment was recorded in Q2 2025. In contrast, Q2 2024 included a $4.1 million goodwill impairment charge.
- Capital Structure: In May 2025, the Company completed a public offering raising approximately $7.5 million in gross proceeds through the sale of common stock, pre-funded warrants, and common warrants. This significantly increased the share count and diluted existing shareholders.
Guidance, Outlook, and Risks
- Clinical Milestones: The Company announced positive topline data from the VIRAGE Phase 2b trial in PDAC, showing a median overall survival of 10.8 months for the VCN-01 arm versus 8.6 months for the control arm. Additionally, Phase 1 data for VCN-01 in retinoblastoma demonstrated promising antitumor activity and tolerability.
- Liquidity and Going Concern: The filing contains a substantial doubt regarding the Company's ability to continue as a going concern. As of early August 2025, cash on hand was approximately $9.5 million. Management believes this is sufficient to fund operations into the first quarter of 2026 but is insufficient to fund operations for the next twelve months or to complete future Phase 3 trials without additional financing.
- Financing Needs: The Company is actively pursuing additional equity or debt financing, including potential private placements, public offerings, or strategic partnerships. There are no committed sources of financing at this time.
- Contingent Consideration: The Company is obligated to pay $6 million to Grifols following the VIRAGE trial success. An agreement was reached to defer the majority of this payment ($5 million) until a licensing or business development transaction is secured.
- Risks: Key risks include the inability to secure necessary funding, delays in clinical trials, failure to achieve regulatory approval, and the impact of global economic conditions on supply chains and costs.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance and burn rate to confirm the "first quarter of 2026" liquidity estimate remains valid given recent market conditions.
- Financing Progress: Monitor for announcements regarding the status of the May 2025 offering proceeds usage and any new financing agreements or partnership deals.
- Contingent Payment Terms: Review the specific terms of the deferred $5 million milestone payment to Grifols and the conditions required to trigger it.
- Phase 3 Planning: Assess the Company's detailed plan and budget for the proposed Phase 3 trial in PDAC, as current cash is explicitly stated as insufficient for this stage.
- Dilution Impact: Analyze the impact of the May 2025 offering and outstanding warrants on future earnings per share and shareholder ownership.